PTAFR and non-small cell lung carcinoma: Along similar lines, we have shown that targeted therapies, gefitinib and erlotinib treatment to A549 and H1299 NSCLC cell lines produce MVP release in a PAFR-dependent manner, in a process blocked by PAFR antagonist or PAFR silencing [28].